ET-STEM

Phase 1Small molecule

SSamsung Medical Center

ET-STEM is one of 27 small molecule programs targeting Frontotemporal Dementia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Frontotemporal DementiaActive, not recruiting

Frontotemporal DementiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

38 competitors in Frontotemporal Dementia

#DrugCompanyPhaseTrials

Namenda

AbbVie

Approved

2 2

Celexa

AbbVie

Approved

1 3

Gocovri

GGrupo Espanol de Tumores Neuroendocrinos

Approved

1 4

Rapamune

PPrism Pharmaceuticals

Rayos

Glucophage

Namenda

1 8

Brintellix

Takeda

Phase 2

1 9

Tasmar

BBausch Health Americas, Inc.

Phase 2

1 10

Lithobid

SSolvay Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Frontotemporal Dementia

NCT05315661

Clinical

Trials by Indication[1]

Frontotemporal Dementia1 trial

The Safety and The Efficacy Evaluation of ET-STEM in Patients With Frontotemporal Dementia

Active, not recruiting·SSamsung Medical Center·Phase 1·NCT05315661·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ET-STEM. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ET-STEM compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ET-STEM. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Samsung Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSamsung Medical Center

ET-STEM

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Frontotemporal Dementia1 trial

References

Drug Info

Quick Facts

Related News